International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“Congrats to Dr. Hideko Isozaki, Professor in Devision of Genome Biology at Kanazawa University Cancer Research Institute! One of our 2025 Early Career Grant Awardees!
Their project, Targeting APOBEC3A as a New Therapy to Prevent Acquired Resistance Targeted Therapy in Non-Small Cell Lung Cancer, reveals that targeted therapy induces APOBEC3A expression in DTPs, promoting their genomic evolution and facilitating resistance. Over 70% of NSCLC tumors treated with TKIs exhibit high APOBEC-associated mutational signatures, highlighting the clinical relevance of this pathway. Crucially, genetic ablation of APOBEC3A preserves genomic stability in DTPs and delays the onset of resistance, supporting its potential as a therapeutic target.
We’re excited to see where this research leads, way to go, Dr. Isozaki!”
More posts featuring IASLC on OncoDaily.